At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
NYS Entity Status
NYS Filing Date
MARCH 31, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - MADISON CONSULTING & DEVELOPMENT CORP.
AROUND THE WEB
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
- Harvey Techies Pass Baton, And APIs, To Florida Peers as Irma Nears
By Angela Shah - Friday Sep 8, 2017
Houston—As Tropical Storm Harvey made landfall in Houston, Florida resident Leah Halbina messaged friends in the city asking how she could help. That was how she found out about Sketch City and the various civic tech projects the group and others were developing to aid rescue efforts, help people find shelter, and tend to other […]
- Ashley Madison owner to pay $11.2M settlement over data breach
By Reuters - Saturday Jul 15, 2017
The owner of the Ashley Madison adultery website said on Friday it will pay $11.2 million to settle U.S. litigation brought on behalf of roughly 37 million users whose personal details were exposed in a July 2015 data breach. Ruby Corp, formerly known as Avid Life Media Inc, denied wrongdoing in agreeing to the preliminary...
- Insurance Giant Aetna Is Leaving Hartford for New York City
By SARAH MASLIN NIR - Thursday Jun 29, 2017
Aetna will move to new headquarters in Manhattan, drawn by New York’s emergence as a digital powerhouse, as well as financial incentives.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]